Quick Links

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.


PER Pulse™ Recaps
for the 3rd Annual Miami Lung Cancer Conference® focus on clinical pearls from the expert Medical Crossfire® panel discussions regarding key therapeutic areas including immunotherapy, oncogene-targeted therapy, and patients with a poor performance status.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Astellas, AstraZeneca, Bristol-Myers Squibb, Celgene, Clovis Oncology, Foundation Medicine, Inc., Genentech, Inc., Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.

For further information concerning Lilly grant funding visit

Medical Crossfire®: 3rd Annual Miami Lung Cancer Conference®

Release Date: May 31, 2016
Expiration Date: May 31, 2017
Media: Internet - based

Activity Overview

This edition of Medical Crossfire®, filmed in conjunction with the 3rd Annual Miami Lung Cancer Conference®, is designed to provide a dynamic discussion of current and evolving paradigms in the treatment of lung cancer, including immunotherapies in development, molecular subsets, targeted agents in development, and the role of cytotoxic agents in the molecular age.

Our Program Chairs, Thomas J. Lynch, Jr., MD, and Heather A. Wakelee, MD, and our expert faculty, Charu Aggarwal, MD, MPH, Christina Baik, MD, MPH, Sarah B. Goldberg, MD, MPH, Rebecca S. Heist, MD, MPH, Edward S. Kim, MD, Sukhmani K. Padda MD, Rathi Pillai, MD, Karen L. Reckamp, MD, Gregory Riely, MD, PhD, and Thomas Stinchcombe, MD, will emphasize the cutting-edge clinical research that will shape the therapy of lung cancer in the near future. Our community oncology representatives, Debra S. Brandt, MD, and Carrie B. Wasserman, MD, will complement the academic perspective provided by our faculty.

Each brief, 10-minute presentation will be followed by an extensive question-and-answer segment led by either, Dr. Lynch or Dr. Wakelee. This extended discussion format will allow ample time for examining the nuances and challenges faced by clinicians in everyday practice, and include a discussion of strategies for applying emerging data to clinical practice to improve outcomes for patients.

CME Activity Table of Contents

  • Panel I: Mutation-Independent Approaches
  • Panel II: Immunotherapy Comes of Age in Lung Cancer
  • Panel III: Targeting Oncogenic Drivers in NSCLC
  • Panel IV: Treatment of Less-Addressed Subgroups

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward oncologists involved in the treatment and management of patients with lung cancers. Nurse practitioners (NPs), nurses, physician assistants (PAs), pharmacists, researchers, fellows, and other health care professionals, interested in the treatment of lung cancers, may also participate.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:
  • Discuss evidence-based recommendations regarding tumor tissue testing and its role in therapeutic selection for the patients with NSCLC
  • Assess clinical decision making necessary along multiple lines of care concerning the use of chemotherapeutic, targeted, and immuno-oncology strategies in the setting of NSCLC
  • Discuss evolving data sets on immuno-oncology strategies and their use in lung cancers
  • Describe the role of cytotoxic and antiangiogenic approaches in the management of advanced NSCLC
  • Explain optimized strategies to target oncogenic drivers in frontline settings and beyond disease progression
  • Describe advances and future directions for care in the management of squamous NSCLC, as well as treatment considerations for special populations of patients with lung cancer
  • Integrate personalized approaches to manage challenging cases and real-world clinical scenarios in advanced lung cancer settings

Faculty, Staff, and Planners' Disclosures

Program Co-Chairs

Thomas J. Lynch, Jr., MD
Chairman and Chief Executive Officer
Massachusetts General Physicians Organization
Boston, MA


Heather A. Wakelee, MD
Associate Professor, Medicine (Oncology)
Stanford University Medical Center
Stanford, CA


Charu Aggarwal, MD, MPH
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Philadelphia, PA


Christina Baik, MD, MPH
Thoracic, Head and Neck Medical Oncology Seattle Cancer Care Alliance Fred Hutchinson Cancer Research Center University of Washington
Seattle, WA


Debra S. Brandt, DO
Smilow Cancer Hospital at Yale-New Haven
New Haven, CT


Sarah B. Goldberg, MD, MPH
Assistant Professor of Internal Medicine
Medical Oncology
Yale Cancer Center
New Haven, CT


Rebecca S. Heist, MD, MPH
Assistant Professor, Department of Medicine, Harvard Medical School
Assistant Professor in Medicine
MGH Cancer Center, Massachusetts General Hospital
Boston, MA

Edward S. Kim, MD
Chair of Solid Tumor Oncology and Investigational Therapeutics
Donald S. Kim Distinguished Chair for Cancer Research
Levine Cancer Institute
Carolinas HealthCare System
Charlotte, NC

Sukhmani K. Padda MD
Instructor of Medicine
Stanford University Medical Center
Stanford, CA


Rathi Pillai, MD
Assistant Professor
Department of Hematology and Oncology
Winship Cancer Institute
Emory University
Atlanta, GA

Karen L. Reckamp, MD
Associate Professor
City of Hope Comprehensive Cancer Center
Duarte, CA


Gregory Riely, MD, PhD
Vice Chair, Clinical Trials Office
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, NY


Tom Stinchcombe, MD
Thoracic Oncology Program
University of North Carolina at Chapel Hill
Chapel Hill, NC


Carrie B. Wasserman, MD
John Theurer Cancer Center
Hackensack UMC at Palisades
North Bergen, NJ


The following individuals have no relevant financial relationships with commercial interests to disclose:

Debra S. Brandt, MD; Rathi Pillai, MD; The staff of Physicians' Education Resource®, LLC.

The following individuals have relevant financial relationships with commercial interests to disclose:

Charu Aggarwal, MD, MPH -- Grant/Research Support: Nektar Therapeutics, Takeda; Consultant: Genentech; Christina Baik, MD, MPH -- Grant/Research Support: Celgene, Genentech, Novartis, Clovis, Millennium; Consultant: Clovis, Novartis; Sarah B. Goldberg, MD, MPH -- Grant/Research Support: AstraZeneca; Consultant: Clovis; Rebecca S. Heist, MD, MPH -- Consultant: Boehringer Ingelheim, Momenta Pharmaceuticals; Edward S. Kim, MD -- Consultant: Celgene, Eli Lilly, AstraZeneca; Thomas J. Lynch, Jr, MD -- Board of Directors for Bristol-Myers Squibb-Honoraria, Stock; Scientific Advisory Board for Arvinas-Honoraria, Stock; Stockholder in Infinity Pharmaceuticals, Stock; Patent Holder: Partners Healthcare EGFR mutation testing patent, Royalties; Sukhmani Padda, MD -- Consultant: Clovis; Karen L. Reckamp, MD -- Consultant: Amgen, Astellas, Ariad, Boehringer Ingelheim; Gregory Riely, MD, PhD -- Grant/Research Support: Roche, Novartis, Infinity, Millennium, GlaxoSmithKline, Pfizer; Consultant: Novartis; Thomas Stinchcombe, MD -- Grant/Research Support: Genentech, Merck Serono, BMS, Threshold Pharmaceuticals; Consultant: BMS, Ariad, Helsinn Therapeutics, Inc., BI, Celgene, AbbVie; Carrie B. Wasserman, MD -- Speaker's Bureau: INSYS Therapeutics. Heather A. Wakelee, MD -- Grant/Research Support: Novartis, BMS, Clovis, Xcovery, Celgene, Roche/Genentech, MedImmune, Pfizer, Lilly; Consultant: Peregrine Pharmaceuticals, Novartis, ACEA Biosciences.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Become a Member

Forgot Password?
Calendar of Events
Filter By